Remove BioTech Remove Digital Health Remove Health Policy Remove Patient Experience
article thumbnail

In U.S. Health Care, It’s Still the Prices, Stupid – But Transparency and Consumer Behavior Aren’t Working As Planned

Health Populi

I’m glad to be getting back to health economic issues after spending the last couple of weeks firmly focused on consumers, digital health technologies and CES 2019. There’s a lot for me to address concerning health care costs based on news and research published over the past couple of weeks.

BioTech 160
article thumbnail

Will Technology Cure Americans’ Health Care System Ills? Considering Google and Ascension Health’s Data Deal

Health Populi

What’s underneath that macro “healthcare” index number of 67 is a precipitous decline in the past year for Americans’ trust in hospitals, compared with biotech, pharma, consumer healthcare, and even health insurance — all of which grew in trust between 2018 and 2019, but not so with the hospital segment of U.S.

BioTech 160
article thumbnail

A Matter of Trust, Perception, Risk, and Uncertainty – The Big Issues Raised by the Acquisition of PatientsLikeMe and Other Patient Data Transactions

Health Populi

To address that challenge, in 2017 PLM secured a $100 million (controlling interest) investment from iCarbonX , a Chinese company that is amassing patient data to discover cures for disease. When this occurred, it didn’t cause more than a ripple of interest outside biotech. But the U.S. citizens’ personal data.